Healthcare Industry News: Tissue Repair
News Release - May 5, 2008
Timothy F. Floeder Joins Synovis Life Technologies as Vice President of Corporate Development
ST. PAUL, Minn.--(HSMN NewsFeed)--Synovis Life Technologies, Inc. (Nasdaq: SYNO ), has named Timothy F. Floeder to the new position of vice president of corporate development, effective immediately. At Synovis, he will be responsible for identifying and acquiring or licensing products synergistic with current sales call points in bariatric, general, vascular, micro and reconstructive surgery.“Tim’s hire reflects the importance we are placing on augmenting the company’s organic growth with external expansion,” said Richard W. Kramp, Synovis president and chief executive officer. “Tim is a key addition to my management team, and I am happy to have him on board. He comes with the experience, energy and expertise to help drive our external business growth.”
Floeder has more than 25 years of experience analyzing and negotiating acquisition, licensing and partnering transactions, and providing corporate finance and financial advisory services to small- and middle-market public and private companies. Prior to joining Synovis, Floeder served as vice president of business development for Compex Technologies, Inc., and as interim CEO/managing director of Compex S.A., its European subsidiary. Previously, he managed merger and acquisition services for Miller, Johnson, Steichen and Kinnard, where he worked with companies in many industries, including medical. In addition, Floeder was chief financial officer for Parsons Electric Company, a privately held electrical contractor.
He received a master’s of business administration in finance from the Carlson School of Management at the University of Minnesota, and a bachelor’s degree in accounting, also from the University of Minnesota.
About Synovis Life Technologies
Synovis Life Technologies, Inc., based in St. Paul, Minn., is a diversified medical device company that develops, manufactures and markets medical devices for the surgical treatment of disease. The company’s products include implantable biomaterials for soft Tissue Repair, devices for microsurgery and surgical tools – all designed to reduce risks and facilitate critical surgeries, leading to better patient outcomes and/or lower costs. For additional information on Synovis Life Technologies and its products, visit the company’s Web site at www.synovislife.com.
Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as “should”, “could”, “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “continue”, or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include the timing of product introductions, the ability of our expanded sales force to grow revenues, outcomes of clinical and market trials as well as regulatory submissions, the number of certain surgical procedures performed, the ability to identify, acquire and successfully integrate suitable acquisition candidates, the cost and outcome of intellectual property litigation, current market conditions affecting our short-term and long-term investments, as well as the other factors found in the company’s Annual Report on Form 10-K for the year ended October 31, 2007.
Source: Synovis Life Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!